Chapter 42
Medical Interventions for Diabetic Retinopathy
Bernd Richter,
Eva Kohner,
Bernd Richter
Search for more papers by this authorEva Kohner
Search for more papers by this authorBernd Richter,
Eva Kohner,
Bernd Richter
Search for more papers by this authorEva Kohner
Search for more papers by this authorBook Editor(s):Richard Wormald,
Liam Smeeth,
Katherine Henshaw,
Anupa Shah,
Richard Wormald
Consultant Ophthalmologist, Moorfields Eye Hospital, Honorary Senior Lecturer, London School of Hygiene and Tropical Medicine and Coordinating Editor, Cochrane Eyes and Vision, Group, London, UK
Search for more papers by this authorLiam Smeeth
Senior Lecturer in Clinical Epidemiology, London School of Hygiene and Tropical Medicine, General Practitioner, London and Editor, Cochrane Eyes and Vision Group, London, UK
Search for more papers by this authorKatherine Henshaw
Review Group Coordinator, Cochrane Eyes and Vision Group, London, UK
Search for more papers by this authorAnupa Shah
Trial Search Coordinator, Cochrane Eyes and Vision Group, London, UK
Search for more papers by this authorSummary
This chapter contains section titled:
-
Background
-
The Evidence
-
Comment
-
Summary
-
Implications for Practice
-
Implications for Research
-
References
References
- Klein R, Klein BEK. Vision disorders in diabetes. In: Diabetes in America. 2nd edn. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995, pp. 293–338.
- Klein R, Klein BE, Moss SE. The Wisconsin epidemiological study of diabetic retinopathy: a review. Diabetes Metab Rev 1989; 5: 559–70.
- Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98: 823–33.
- Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991; 98: 786–806.
- Rand LI, Prud’homme GJ, Ederer F, Canner PL. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci 1985; 26: 983–91.
- Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91: 1–9.
- Roy MS. Diabetic retinopathy in African Americans with type 1 diabetes: The New Jersey 725: II. Risk factors. Arch Ophthalmol 2000; 118: 105–15.
- Sjolie AK, Stephenson J, Aldington S et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 1997; 104: 252–60.
- Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–32.
- Tielsch JM, Sommer A, Witt K, Katz J, Royall RM. Blindness and visual impairment in an American urban population. The Baltimore Eye Survey. Arch Ophthalmol 1990; 108: 286–90.
- Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464–74.
- Stratton IM, Kohner EM, Aldington SJ et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156–63.
- Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group. Diabetologia 1999; 42: 1107–12.
- Klein R, Meuer SM, Moss SE, Klein BE. The relationship of retinal microaneurysm counts to the 4-year progression of diabetic retinopathy. Arch Ophthalmol 1989; 107: 1780–5.
- Klein R, Meuer SM, Moss SE, Klein BE. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 1995; 113: 1386–91.
- Reichard P. Risk factors for progression of microvascular complications in the Stockholm Diabetes Intervention Study (SDIS). Diabetes Res Clin Pract 1992; 16: 151–6.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53.
- Anonymous. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968–83.
- Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care 1998; 21: 1230–5.
- Klein R, Klein BEK, Moss SE. Severe retinopathy in insulin-taking children and young adults. Pediatr Adolesc Endocrinol 1988; 17: 146–52.
- Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. XL The incidence of macular edema. Ophthalmology 1989; 96: 1501–10.
- Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989; 149: 2427–32.
- Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R. Blood pressure, retinopathy and urinary albumin excretion in 1DDM: the EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 599–603.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
- Sigurdsson R, Begg IS. Organised macular plaques in exudative diabetic maculopathy. Br J Ophthalmol 1980; 64: 392–7.
- Chew EY, Klein ML, Ferris FL et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114: 1079–84.
- Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991; 98: 1261–5.
- Ferris FL, HI, Chew EY, Hoogwerf BJ. Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. Diabetes Care 1996; 19: 1291–3.
- Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complicaüons Trial. Ophthalmology 1995; 102: 647–61.
- Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13: 34–40.
- Rosenn B, Miodovnik M, Kranias G et al. Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy. Am J Obstet Gynecol 1992; 166: 1214–18.
-
Lovestam-Adrian M,
Agardh CD,
Aberg A,
Agardh E.
Pre-eclampsia is a potent risk factor for deterioration of retinopathy during pregnancy in Type 1 diabetic patients.
Diabet Med
1997;
14:
1059–65.
10.1002/(SICI)1096-9136(199712)14:12<1059::AID-DIA505>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- Klein BE, Klein R, Meuer SM, Moss SE, Dalton DD. Does the severity of diabetic retinopathy predict pregnancy outcome? J Diabetes Complications 1988; 2: 179–84.
- Moss SE, Klein R, Klein BE. The association of alcohol consumption with the incidence and progression of diabetic retinopathy. Ophthalmology 1994; 101: 1962–8.
- Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996; 103: 1438–42.
- Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178–84.
- Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98: 823–33.
- Davis MD, Fisher MR, Gangnon RE et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report 18. Invest Ophthalmol Vis Sci 1998; 39: 233–52.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977–86.
- Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983; 1: 200–4.
- Anonymous. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995; 113: 36–51.
- Chantelau E, Kohner EM. Why some cases of retinopathy worsen when diabetic control improves. BWJ 1997; 315: 1105–6.
- Diabetes care and research in Europe: the Saint Vincent declaration. Diabet Med 1990; 7: 360.
- Hutchinson A, Mcintosh A, Peters J et al. Effectiveness of screening and monitoring tests for diabetic retinopathy - a systematic review. Diabet Med 2000; 17: 495–506.
- British Diabetic Association. Retinal photography screening for diabetic eye disease. A British Diabetic Association Report. London: British Diabetic Association, 1997.
- Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. J Epidemiol Community Health 1998; 52: 45–52.
- Harding SP, Broadbent DM, Neoh C, White MC, Vora J. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ 1995; 311: 1131–5.
- Taylor R, Lovelock L, Tunbridge WM et al. Comparison of non-mydriatic retinal photography with ophthalmoscopy in 2159 patients: mobile retinal camera study. BMJ 1990; 301: 1243–7.
- Porta M, Kohner E. Screening for diabetic retinopathy in Europe. Diabet Med 1991; 8: 197–8.
- Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulindependent) diabetes mellitus? Diabetologia 2000; 43: 125–30.
- Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000; 283: 889–96.
- Anonymous. A Randomized Trial of Sorbinil, an Aldose Reductase Inhibitor, in Diabetic Retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol 1990; 108: 1234–44.
- Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P. The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications 1992; 6: 131–7.
- Biersdorf WR, Malone JI, Pavan PR, Lowitt S. Cone electroretinograms and visual acuities of diabetic patients on sorbinil treatment. Doc Ophthalmol 1988; 69: 247–54.
- Cunha-Vaz JG, Mota CC, Leite EC, Abreu JR, Ruas MA. Effect of sorbinil on blood-retinal barrier in early diabetic retinopathy. Diabetes 1986; 35: 574–8.
- Hosotani H, Ohashi Y, Yamada M, Tsubota K. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol 1995; 119: 288–94.
- Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol 1991; 78: 153–9.
- van Gerven JM, Boot JP, Lemkes HH, van Best JA. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol 1994; 87: 355–65.
- Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28–31.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–20.
- Archimowicz CB. Clinical effect of buckwheat herb, Ruscus extract and troxerutin on retinopathy and lipids in diabetic patients. Phytother Res 1996; 10: 659–62.
- Bursell SE, Clermont AC, Aiello LP et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999; 22: 1245–51.
- Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy - a systematic review. Endocrinol Metab Clin North Am 2002; 31: 779–93.
- ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268: 1292–300.
- Belgian Ticlopidine Retinopathy Study Group (BTRS). Clinical study of ticlopidine in diabetic retinopathy. Ophthalmology 1992; 204: 4–12.
- The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990; 108: 1577–83.
- Haas A. Effect of calcium dobesilate on progression of diabetic retinopathy. Klin Monatsbl Augenheilkunde 1995; 207: 17–21.
- Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991; 23: 12–20.
- Salama Benarroch I, Nano H, Perez H, Elizalde F, Bisceglia H, Salama A. Assessment of calcium dobesilate in diabetic retinopathy. A double-blind clinical investigation. Ophthalmology 1977; 174: 47–51.
- Daubresse JC, Meunier R, Dumont P. A controlled clinical trial of calcium dobesylate in the treatment of diabetic retinopathy. Diabetes Metabol 1977; 3: 27–30.
- Freyler H. Microvascular protection with calcium dobesilate (Doxium) in diabetic retinopathy. Ophthalmology 1974; 168: 400–16.
- Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia 1977; 13: 105–9.
- Stamper RL, Smith ME, Aronson SB et al. The effect of calcium dobesilate on nonproliferative diabetic retinopathy: a controlled study. Ophthalmology 1978; 85: 594–606.
- Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1974; 94: 554–62.
- Cunha-Vaz JG, Reis Fonseca J, Hagenouw JR. Treatment of early diabetic retinopathy with cyclandelate. Br J Ophthalmol 1977; 61: 399–404.
- Mota MC, Leite E, Ruas MA, Verjans HL, Blakemore CB, Cunha-Vaz JG. Effect of cyclospasmol on early diabetic retinopathy. Int Ophthalmol 1987; 10: 3–9.
- van der Pijl JW, van der Woude FJ, Swart W, Van Es LA, Lemkes HH. Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet 1997; 350: 1743–5.
- van der Pijl JW, Lemkes HH, Frolich M, van der Woude FJ, van der Meer FJ, Van Es LA. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol 1999; 10: 1331–6.
- Bandello F, Lattanzio R, Maestranzi G, Brancato R. Bovine factor VIII derivative in the treatment of non-proliferative diabetic retinopathy. Ophthalmologica 1995; 209: 149–54.
- Lanthony P, Cosson JP. The course of color vision in early diabetic retinopathy treated with Ginkgo biloba extract. A preliminary double-blind versus placebo study. J Fr Ophtalmol 1988; 11: 671–4.
- Hunter PR, Cotton SG, Kelsey JH, Bloom A. Controlled trial of methandienone in treatment of diabetic retinopathy. BMJ 1967; 3: 651–3.
- Klein M, Hirche H. Naftidrofuryl in the treatment of simple diabetic retinopathy. A double-blind study. Klin Monatbl Augenheilkunde 1985; 187: 195–201.
- Sonkin PL, Kelly LW, Sinclair SH, Hatchell DL. Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. Arch Ophthalmol 1993; 111: 1647–52.
- Grant MB, Mames RN, Fitzgerald C et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504–9.
- Kirkegaard C, Norgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinol 1990; 122: 766–72.
- Cunha-Vaz JG, Mota CC, Leite EC, Abreu JR, Ruas MA. Effect of sulindac on the permeability of the blood-retinal barrier in early diabetic retinopathy. Arch Ophthalmol 1985; 103: 1307–11.
- Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002; 133: 693–8.
